All sponsors

Fujian Shengdi Pharmaceutical Co., Ltd.

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS21
PHASE 3 / 2-38
RECRUITING11
READOUTS ≤12 MONTHS12
READOUT SLIPPED >6 MO0%

Delay Index: of 7 active trials registered more than a year ago, 0 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open Fujian Shengdi Pharmaceutical Co., Ltd. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
HRS9531
NCT06391710
P2Active, not recruitingHeart Failure With Preserved Ejection Fraction2032026-01 (+4 mo)
HRS-5635 Injection
NCT06425341
P2RecruitingChronic Hepatitis B3692026-08-30 (+4 mo)
HRS-7249 Injection
NCT07100418
P2Active, not recruitingHyperlipidemia2242026-09
HRS-9057 injection set
NCT07318103
P2RecruitingFluid Retention Caused by Heart Failure1532026-09
HRS5580 for injection combined with palonosetron hydrochloride;
NCT07709897
P2RecruitingPrevention of Postoperative Nausea and Vomiting2602026-12
HRS-9563 Injection
NCT07297797
P2Active, not recruitingMild to Moderate Hypertension2382026-12
HRS9531
NCT06994650
P3Active, not recruitingSubjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy1442026-12
HRS9531
NCT06974851
P3RecruitingBstructive Sleep Apnea (OSA) and Obesity1402026-12
HRS9531
NCT07060456
P3RecruitingType 2 Diabetes3002027-02
HRS-4729 Injection
NCT07690826
P2Not yet recruitingOverweight or Obesity2522027-03
HRS9531 injection
NCT07285902
P3Active, not recruitingObesity5722027-03
HRS-5632 Injection
NCT07185776
P2Active, not recruitingLipoprotein Disorder2032027-04
HRS-4729 Injection
NCT07843862
P2Not yet recruitingType 2 Diabetes2402027-04
HRS9531 Tablet
NCT07599410
P2RecruitingT2DM2402027-05
HRS-7249 injection set
NCT07308392
P2Active, not recruitingSevere Hypertriglyceridemia With a High Risk of Acute Pancreatitis1192027-06
HRS9531 Tablet
NCT07670884
P3RecruitingChronic Management of Body Weight6752027-10-31
HRS-4729 Injection
NCT07660848
P2RecruitingMetabolic Dysfunction-Associated Steatohepatitis (MASH)1602028-03
HRS-5635 Injection
NCT07606950
P3RecruitingNucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B5402028-06
HRS-7249 Injection
NCT07799688
P2RecruitingHyperlipidemia4002028-10-15
Ribupatide Injection
NCT07709910
P3Not yet recruitingParticipants With Obesity and Knee Osteoarthritis3822028-11
HRS9531
NCT07551492
P3RecruitingAtherosclerotic Cardiovascular Disease92622031-05-24